Compare Brunswick Corporation (BC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs GeneDx Holdings Corp — how do they compare? Brunswick Corporation trades at $79.32 (market cap $5.04B), while GeneDx Holdings Corp trades at $62.64 (market cap $1.85B). The key difference: Brunswick Corporation is far larger — about 2.7× GeneDx Holdings Corp's market cap, and Brunswick Corporation pays a 2.27% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BC | WGS | |
|---|---|---|
Market Cap | $5.04B | $1.85B |
Sector | Consumer Cyclical | Technology |
52-Week High | $89.22 | $167.51 |
52-Week Low | $56.64 | $34.51 |
Enterprise Value | $7.20B | $1.85B |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BC's stock trades at $76.95, down 1.22% on the day, with a bearish technical signal and support near $76. The company reported a net loss of $137.30 million in 2025 despite revenue of $5.36 billion, though recent earnings beat expectations. Analyst consensus is strongly bullish with a $86.40 price target, and the company continues expanding its Freedom Boat Club business.
The outlook is mixed: strong analyst support and operational cash flow of $562.10 million in 2025 provide upside potential, but negative profit margins and high P/E of 73.92 pose valuation risks. Investors face headwinds from profitability challenges despite positive sentiment from Wall Street.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
